Stock Analysis

On 2 October 2026, Fisher & Paykel Healthcare shares were trading at $36.79, down 1.50%. The company's financial year runs to 31 March, and in August it provided first-half guidance for the 2027 financial year and updated its full-year outlook.

On 2 October 2026, IDX shares were trading at $2.15, up 0.94%. The company reports in Australian dollars, and its financial year ends on 30 June. Its most recent full-year results, released in August, covered the first full year including the Capitol business.

On 2 October 2026, Mesoblast shares were trading at $2.04 on the ASX, down 1.45%. Its full-year results, released in August, covered the first full year of RYONCIL's US launch.

On 2 October 2026, Nanosonics shares were trading at $2.88, up 0.35%. The company reports in Australian dollars but generates most of its revenue in US dollars. Its full-year results, released in August, covered trophon performance, CORIS progress and guidance for the 2027 financial …

On 2 October 2026, Neuren shares were trading at $20.28, up 0.70%. The company reports on a calendar-year basis, and its half-year results to 30 June 2026 introduced its firstDividendpolicy.

On 2 October 2026, Pro Medicus shares were trading at $156.38, down 2.92%. The company's full-year results, released in August, reportedRevenueandEarningsgrowth and a series of new contracts.

On 2 October 2026, PYC shares were trading at $2.46, down 1.99%. As a clinical-stage company, PYC does not yet generate product revenue, and its value is largely linked to the progress of itsDrug Developmentprograms.